SMTL ID : 8bdi.4 (3 other biounits)

VCB in complex with compound 32

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.11 Å

Oligo State

hetero-1-1-1-mer

Ligands

1 x QF7: (2~{S},4~{R})-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-~{N}-[(1~{S})-3-(methylamino)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-4-oxidanyl-pyrrolidine-2-carboxamide(Non-covalent)

QF7.1: 16 residues within 4Å: Chain C: N.16, R.18, P.35, W.37, F.40, Q.45, Y.47, P.48, R.56, R.57, I.58, H.59, S.60, Y.61, H.64, W.66 14 PLIP interactions: 14 interactions with chain C Hydrophobic interactions: C:R.18, C:W.37, C:W.37, C:Y.47, C:Y.47, C:I.58, C:Y.61, C:W.66 Hydrogen bonds: C:W.37, C:R.56, C:H.59, C:H.59, C:Y.61, C:H.64

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Krieger, J. et al., Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design. Chemmedchem (2023)

Release Date

2023-02-15

Peptides

Elongin-B: A
Elongin-C: B
von Hippel-Lindau disease tumor suppressor: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
C

Elongin-B

Elongin-C

von Hippel-Lindau disease tumor suppressor

Related Entries With Identical Sequence